AlloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells

ABSTRACT: The purpose of the alloSHRINK study is to assess the safety, cell kinetics and clinical activity of CYAD-101 in patients with unresectable metastatic colorectal cancer administered after standard chemotherapy

DISEASE(S): Unresectable Metastatic Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2285775 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR